DisclosureWe earn commission on partner links; ranking is set by clinician-vetted methodology — not advertisers.
GLP-1s reduce alcohol craving (ATTAIN-1 trial confirmed). Moderate drinking is not contraindicated but amplifies side effects. Here is the safe-use framework + the AUD evidence.
GLP-1 receptors exist in dopaminergic reward circuits — the same pathways that drive cravings for food and alcohol. Semaglutide and tirzepatide blunt the reward response, reducing the salience of drinking. Combined with slowed gastric emptying (alcohol absorption changes) and increased satiety (fewer drinks fit), patients drink less.
ATTAIN-1 (Phase 2, NIH-funded, 2024) enrolled 48 adults with alcohol use disorder. Semaglutide 1.0 mg weekly vs placebo for 9 weeks. Result: ~30% reduction in heavy drinking days on semaglutide arm. Phase 3 program enrolling 2025-2026.
Editorial summary, not medical advice. AUD treatment should be coordinated with addiction medicine. AA, naltrexone, acamprosate, and counseling remain primary therapy for AUD.